UH Seidman Cancer Center physician-scientists and clinical researchers push the boundaries of medical science in the fight against cancer through laboratory investigation and clinical trials for patients. As part of the National Cancer Institute (NCI)-designated Case Comprehensive Cancer Center at Case Western Reserve University, UH Seidman Cancer Center is engaged in early phase clinical trials and new drug development. Our patients have access to more than 300 ongoing trials.
A strong emphasis on translational research means new scientific discoveries move more rapidly from laboratory to bedside.
A recent study of mesenchymal stromal cells used to expand umbilical cord blood may change the standard of care in stem cell transplantation, with reduced infections and less dependence on transfusions.
CLINICAL TRIALS HIGHLIGHTS
Clinical Trials Highlights - Acute Leukemia, Hematology Update - Fall 2017
Innovative trial to reduce the likelihood of blood cancers relapse after treatment. The trial has two objectives: to prevent rejection of donor cells and reduce the side effects of whole body radiation by targeting therapies to just the bone marrow.
A new, multi-institutional, Phase III study of algenpantucel-L – a pancreatic cancer vaccine – is designed to trigger a patient’s own immune system to destroy cancer cells and extend survival.
An ongoing clinical trial of a promising noninvasive technology for colon cancer screening will compare the effectiveness of stool DNA (sDNA) testing with colonoscopy.
A study of a promising gene marker – KLF6-SV1 – that predicts more aggressive breast cancers will soon be underway to help identify women at-risk and potentially develop targeted, personalized drugs that block metastasis of a mutant gene and reduce breast cancer mortality.
UH Seidman Cancer Center has established the Center for Cancer Drug Development. Created in partnership with Case Western Reserve University, the center brings together biochemists, pharmacologists, animal pathologists, animal and human imaging experts, cancer biologists, medicinal chemists and clinical oncologists to speed the flow of novel cancer therapies from research laboratory to bedside.
New drug developments in early phase clinical trials bring leading-edge treatments to patients earlier than most other cancer centers.
• Methoxyamine, an investigational drug discovered at Case Western Reserve University and has received investigational drug status from the Food and Drug
Administration, is being studied in combination with fludarabine for its ability to block cellular repair of drug-induced DNA damage. This drug combination could change the treatment standard for patients with low-grade lymphoid malignancies, particularly
chronic lymphocytic leukemia (CLL). As part of the study, a large CLL patient database will be established to follow patients over time to determine if there are clinical patterns or markers to predict long-term outcomes.
View complete listing of clinical trials at UH Seidman Cancer Center’s Clinical Trials Database.